NCT07152210撤回不适用
Clinical Study Evaluating the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
Guangzhou Bio-gene Technology Co., Ltd1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年12月11日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Evaluation of Safety
研究概览
简要总结
This study is a single-arm, single-center investigator-initiated trial (IIT) designed to evaluate the safety and preliminary efficacy of CDH17/GUCY2C CAR-T cell therapy in patients with advanced colorectal cancer, as well as to assess its pharmacodynamic (PD) and pharmacokinetic (PK) profiles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in this trial, sign the informed consent form.
- •Advanced colorectal cancer patients who have either failed standard treatment, experienced intolerable toxicity, or are unsuitable or unwilling to undergo standard treatment, and voluntarily agree to receive the current treatment.
- •Be able to provide immunohistochemical (IHC) test results from the past 2 years, indicating positive expression of CDH17/GUCY2C targets in tumor tissues.
- •Have at least one extracranial, measurable/assessable lesion according to RECIST 1.1 criteria.
- •Have an ECOG (Eastern Cooperative Oncology Group) performance status score of 0-1 and an expected survival duration of at least 3 months.
- •Have recovered from the toxicity associated with previous treatments, with a CTCAE toxicity grade of less than
- •Have no significant hematopoietic dysfunction and possess adequate organ function.
- •Be able to meet the research center's requirements for apheresis/peripheral blood collection upon successful screening, or have acceptable stored blood cell separation products available.
排除标准
- •Patients who have had or currently have other malignant tumors within the past five years.
- •Presence of brain metastasis.
- •History of clinically significant central nervous system disorders, either in the past or at screening.
- •Imaging indicating tumor invasion of major blood vessels or indistinct borders with blood vessels.
- •Individuals who have received cytotoxic drugs or other interventions, assessed by the investigator as potentially impacting lymphocyte expansion, within 14 days or at least five half-lives (whichever is shorter) prior to blood collection for CAR-T preparation.
- •Presence of other viremias.
- •History of severe allergies.
- •Patients with severe cardiac disease.
- •Patients with severe hepatic and renal dysfunction or disorders of consciousness.
- •Patients with active autoimmune or inflammatory diseases.
- •Patients with objective evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonia, severe lung function impairment, etc.
- •Patients who have undergone or are awaiting organ transplantation.
- •Infections requiring intravenous antibiotic therapy for control or are uncontrollable.
- •Individuals who have received live (attenuated) virus vaccines within four weeks prior to screening.
- •Alcoholics or individuals with a history of substance abuse.
- •Pregnant or lactating women.
- •Individuals who have participated in other clinical trials involving drugs within the past 30 days.
- •Patients who, based on the investigator's judgment and/or clinical standards, have contraindications to any study procedures or present other medical conditions that may pose unacceptable risks.
研究组 & 干预措施
CAR-T
Experimental
The dosage range of 1.0 × 10^6/kg (± 20%) to 5.0 × 10^6/kg (± 20%) of CAR-T cells, administered either intravenously or intratumorally.
干预措施: CAR-T (Biological)
结局指标
主要结局
Evaluation of Safety
时间窗: Up to 1 year after CAR-T infusion
Count the Incidence of adverse events
Effectiveness evaluation
时间窗: Up to 1 years after CAR-T infusion
In accordance with the RECIST 1.1 criteria for assessing the efficacy of solid tumors, the objective response rate (ORR), encompassing patients achieving complete response (CR) and partial response (PR).
次要结局
- Pharmacokinetic parameters(Up to 1 year after CDH17/GUCY2C CAR-T infusion)
- Pharmacodynamic parameters(Up to 1 year after CAR-T infusion)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid TumorsNCT07152236Guangzhou Bio-gene Technology Co., Ltd20
终止
早期 1 期
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AMLAcute Myeloid LeukemiaNCT06110208920th Hospital of Joint Logistics Support Force of People's Liberation Army of China3
暂停
早期 1 期
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaMultiple MyleomaRefractory and Relapsed Multiple MyelomaNCT06663046Wondercel Biotech (ShenZhen)30
招募中
1 期
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal CancerColorectal Cancer (CRC)NCT06718738Beijing Immunochina Medical Science & Technology Co., Ltd.9
尚未招募
不适用
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid TumorsSolid TumorNCT05745454su haichuan12